You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Dovato is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. 3

Dovato Recommended in Treatment Guidelines

EACS Guidelines

Dovato is recommended as an initial regimen for treatment naïve patients and as a switch strategy for virologically supressed patients 1

Requirements for treatment naïve patients:

  • HBsAg negative 
  • HIV Viral load <500,000 copies/ml
  • CD4 count >200 cells/µL

EACS GUIDELINES 2019

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/eacs-2019-guidelines-update-jose-gatell-video.mp4

DHHS Guidelines

Dovato is recommended as an initial regimen for most PLHIV (AI)*+ and as a good option for virologically suppressed patients who have no evidence of resistance to either drug 2

Exclusions for treatment naïve patients:

  • HIV viral load of >500,000 copies/ml
  • HBV co-infection
  • Where ART is to be started before the results of HIV genotype resistance testing for reverse transcriptase or HBV testing are available

DHHS GUIDELINES 2019

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/dhhs-guidelines-kim-smith-and-chuck-hicks-video.mp4

References:

  1. European AIDS Clinical Society Guidelines Version 10.0. November 2019. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed April 2020.
  2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 2020.
  3. DOVATO Summary of Product Characteristics. https://www.medicines.ie/medicines/dovato-50-mg-300-mg-film-coated-tablets-34871/smpc. Last accessed: June 2020.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.